Correction: BMC Trials 24, 112 (2023)
https://doi.org/10.1186/s13063-023-07087-5
Following publication of the original article [1], we have been notified that affiliations 1 to 4 are actually different titles within the same department and should be gathered under just one affiliation.
Additionally, the following sentence was added in the Funding section: This study was supported by the National High Level Hospital Clinical Research Funding (2022-PUMCH-A-227).
The original article has been corrected.
Reference
Bai, et al. A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren’s syndrome patients. BMC Trials. 2023;24:112. https://doi.org/10.1186/s13063-023-07087-5.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Bai, W., Yang, F., Xu, H. et al. Correction: A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren’s syndrome patients. Trials 24, 487 (2023). https://doi.org/10.1186/s13063-023-07546-z
Published:
DOI: https://doi.org/10.1186/s13063-023-07546-z